Category Archives: Cell Medicine

29-01-2012 20:51 MY DIET PLAN http://www.LeanSecrets.com FACEBOOK http TWITTER http://www.twitter.com STUDIES ------------------------------------------------------------------------------------ ***EFFECTS ON WEIGHT LOSS*** Analysis of lectin binding in benign and malignant thyroid nodules Arch Pathol Lab Med. 1989 Feb;113(2):186-9. http://www.ncbi.nlm.nih.gov Agrarian diet and diseases of affluence and leptin resistance BMC Endocrine Disorders 2005, 5:10 doi:10.1186/1472-6823-5-10 http://www.biomedcentral.com ***EFFECTS ON CELL ADHESION MOLECULE-1*** Department of Laboratory Medicine Biochemistry. 2001 Oct 30;40(43):12992-3001. http://www.ncbi.nlm.nih.gov ***WHEAT LINKED TO HEADACHES*** Headache and CNS white matter abnormalities associated with gluten sensitivity Neurology February 13, 2001 56:385-388 http://www.neurology.org ***WHEAT LINKED TO SKIN ISSUES*** Dermatitis herpetiformis and gluten-free diet Dermatology Online Journal 11 (1): 6 dermatology.cdlib.org Gluten intolerance and skin diseases Department of Dermatology, University of Franche-Comté Eur J Dermatol. 2006 Jan-Feb;16(1):4-11. http://www.ncbi.nlm.nih.gov ***WHEAT IS INFLAMMATORY** Wheat flour exposure results in recruitment of inflammatory cells in the lungs of healthy individuals. Department of Medicine, Division of Respiratory Medicine Am J Ind Med. 2003 Jul;44(1):75-82. http://www.ncbi.nlm.nih.gov Continue reading here: 10 Reasons To Stop Eating Wheat - Video … Continue reading →

31-01-2012 09:30 New gadgets to help you stay healthy for less money! Get a sneak peek at what researchers are working on right now. http://www.ivanhoe.com The rest is here: Health Gadgets of the Future: Medicine's Next Big Thing? - Video … Continue reading →

31-01-2012 09:30 New gadgets to help you stay healthy for less money! Get a sneak peek at what researchers are working on right now. http://www.ivanhoe.com The rest is here: Health Gadgets of the Future: Medicine's Next Big Thing? - Video … Continue reading →

31-01-2012 13:21 Ronald W. Hanson, Jr., MD lectures at the 11th Clinical Applications for Age Management Medicine in November 2011, in Las Vegas, Nevada This focused conference track cocentrated on regenerative and cell-based medicine continue to grow in use by physicians across the world. From platelet rich plasma to culture expanded stem cells, the need for information about the applications of these therapies to treat patients has never been greater. This track will focus on the latest developments in cell-based medicine with speakers who are driving the research and using these technologies as part of their everyday practice of medicine. For more information contact conference@agemed.org Visit our website at agemed.org Follow this link: The Use of Guided Bone Marrow Nucleated Cell Fraction Injections - Ronald W. Hanson, Jr., MD - Video … Continue reading →

31-01-2012 13:32 James P. Watson, MD lecture sample from the 11th Clinical Applications for Age Management Medicine Conference, Fall 2011, Las Vegas, Nevada Pre-Conference Track 2: Regenerative and Cell Based Medicine This lecture focused on regenerative and cell-based medicine, Autologous Stem Cell Research. This field continues to grow in use by physicians across the world. From platelet rich plasma to culture expanded stem cells, the need for information about the applications of these therapies to treat patients has never been greater. This track will focus on the latest developments in cell-based medicine with speakers who are driving the research and using these technologies as part of their everyday practice of medicine. For more information about our upcoming conference visit our website http://www.agemed.org Or contact us at conference@agemed.org Visit link: An Overview of Data Trends in Autologous Stem Cell Research and Clinical Use - James P. Watson, MD - Video … Continue reading →

OTTAWA , Feb. 1, 2012 /CNW/ - The following is a statement by Russell Williams , President of Canada's Research-Based Pharmaceutical Companies (Rx&D) on the announcement by the Government of Canada today to ensure that personalized medicine will allow for more effective treatments, thus supporting our Canadian health care system in a more sustainable way. "Canada's Research-Based Pharmaceutical Companies welcome this commitment by the Government of Canada to establish personalized medicine as the way to transform the delivery of health care to patients. "At Rx&D, we believe that providing the right medicine with the right dose to the right patient at the right time is crucial to improving health outcomes for Canadians. With the rise of chronic disease and an aging population, all governments are grappling with unprecedented demand for health care services. It is clear that we face a collective challenge to sustain and improve our health care system where traditional approaches are no longer efficient. "We commend the Government of Canada's commitment to engage in this work. Pharmaceutical innovation is a proven tool to help Canadians live longer, healthier, more productive lives. It is critical to the future productivity of our country, our workplaces, our communities and our … Continue reading →

OTTAWA , Feb. 1, 2012 /CNW/ - The following is a statement by Russell Williams , President of Canada's Research-Based Pharmaceutical Companies (Rx&D) on the announcement by the Government of Canada today to ensure that personalized medicine will allow for more effective treatments, thus supporting our Canadian health care system in a more sustainable way. "Canada's Research-Based Pharmaceutical Companies welcome this commitment by the Government of Canada to establish personalized medicine as the way to transform the delivery of health care to patients. "At Rx&D, we believe that providing the right medicine with the right dose to the right patient at the right time is crucial to improving health outcomes for Canadians. With the rise of chronic disease and an aging population, all governments are grappling with unprecedented demand for health care services. It is clear that we face a collective challenge to sustain and improve our health care system where traditional approaches are no longer efficient. "We commend the Government of Canada's commitment to engage in this work. Pharmaceutical innovation is a proven tool to help Canadians live longer, healthier, more productive lives. It is critical to the future productivity of our country, our workplaces, our communities and our … Continue reading →

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX - News) announced today that the U.S. Food and Drug Administration (FDA) has approved KALYDECOTM (ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis (CF), a rare, genetic disease. KALYDECO (kuh-LYE-deh-koh) is approved for people with CF ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Approximately 1,200 people in the United States, or 4 percent of those with CF, are believed to have this mutation. KALYDECO was granted approval in approximately three months, making it one of the fastest FDA approvals ever and marking the second approval of a new medicine from Vertex in less than a year. The company has established a financial assistance and patient support program to help get KALYDECO to eligible patients for whom it is prescribed. KALYDECO was discovered as part of a collaboration with Cystic Fibrosis Foundation Therapeutics, Inc., the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation. Vertex is ready to support the introduction of KALYDECO and will begin shipping it to pharmacies in the United States this week. The company will host a … Continue reading →

MANASSAS, Va.--(BUSINESS WIRE)-- The ATCC® Standards Development Organization (ATCC SDO), an entity of ATCC, has published its second voluntary consensus standard, ASN-0002: “Authentication of Human Cell Lines: Standardization of STR Profiling.” This consensus standard is expected to have broad impact across basic cell research, drug discovery, and translational medicine. This approved American National Standard represents a major step forward in correcting the long standing problem of cell line misidentification. The standard’s intent is to delineate a standardized, universally applicable method for authenticating new and established human cell lines and human primary tissue used in research. A living document, the standard will be subject to revisions over time to reflect changes in the field and new methodologies. “This new standard is one example of our commitment to the program mission for the ATCC SDO---to develop and publish stakeholder-proposed, industry-relevant standards for biomaterials and related processes,” said Raymond Cypess, DVM, PhD, Chief Executive Officer for ATCC. “We are creating and maintaining biological standards that protect public interests,” said Dr. Cypess, “and we endeavor to ensure that government, regulatory agencies, industry and academia have the tools and resources to ensure the importance of properly authenticated material for biological research and product development.” Human cell … Continue reading →

24-09-2010 12:47 "60 Minutes" hidden cameras expose medical con men who prey on dying victims by using pitches that capitalize on the promise of stem cells to cure almost any disease. Scott Pelley reports Visit link: 21st Century Snake Oil, Part 1 - Video … Continue reading →